Patents by Inventor Bahija Jallal

Bahija Jallal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170121771
    Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
    Type: Application
    Filed: October 11, 2016
    Publication date: May 4, 2017
    Applicant: MEDIMMUNE, LLC
    Inventors: YIHONG YAO, BAHIJA JALLAL, RICARDO CIBOTTI, ANTHONY COYLE, PETER KIENER
  • Publication number: 20170101468
    Abstract: The present invention provides human anti-IL-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to IL-6 and that has an extended in vivo half-life for the treatment and prevention of IL-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors.
    Type: Application
    Filed: December 2, 2016
    Publication date: April 13, 2017
    Inventors: Michael Bowen, Herren Wu, William Dall'Acqua, Peter Kiener, Bahija Jallal, Anthony Coyle
  • Publication number: 20160024205
    Abstract: The present disclosure encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that modulates type 1 interferon activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
    Type: Application
    Filed: October 6, 2015
    Publication date: January 28, 2016
    Applicant: MEDIMMUNE, LLC
    Inventors: Brandon Higgs, Wei Zhu, Chris Morehouse, Barbara White, Bahija Jallal, Yihong Yao
  • Patent number: 9193789
    Abstract: The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonization) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: November 24, 2015
    Assignee: MedImmune, LLC
    Inventors: Anthony Coyle, Yihong Yao, Bahija Jallal, Gianluca Carlesso, Michael Bowen
  • Publication number: 20150191788
    Abstract: The present disclosure encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that modulates type 1 interferon activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
    Type: Application
    Filed: March 18, 2015
    Publication date: July 9, 2015
    Inventors: BRANDON HIGGS, WEI ZHU, CHRIS MOREHOUSE, BARBARA WHITE, BAHIJA JALLAL, YIHONG YAO
  • Publication number: 20150147336
    Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
    Type: Application
    Filed: January 27, 2015
    Publication date: May 28, 2015
    Inventors: Yihong YAO, Bahija Jallal, Ricardo Cibotti, Anthony Coyle, Peter Kiener
  • Publication number: 20150132313
    Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
    Type: Application
    Filed: September 23, 2014
    Publication date: May 14, 2015
    Inventors: Yihong YAO, Bahija Jallal, Ricardo Ciboti, Anthony Coyle, Peter Kiener
  • Publication number: 20150044222
    Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
    Type: Application
    Filed: July 14, 2014
    Publication date: February 12, 2015
    Applicant: MEDIMMUNE, LLC
    Inventors: Yihong YAO, Bahija JALLAL, Ricardo CIBOTTI, Anthony COYLE, Peter KIENER
  • Publication number: 20140302058
    Abstract: The present invention provides human anti-IL-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to IL-6 and that has an extended in vivo half-life for the treatment and prevention of IL-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors.
    Type: Application
    Filed: April 15, 2014
    Publication date: October 9, 2014
    Applicant: MedImmune, LLC
    Inventors: Michael Bowen, Herren Wu, William Dall'Acqua, Peter Kiener, Bahija Jallal, Anthony Coyle
  • Publication number: 20130230528
    Abstract: Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.
    Type: Application
    Filed: December 17, 2012
    Publication date: September 5, 2013
    Applicants: XOMA TECHNOLOGY LTD., NOVARTIS AG
    Inventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
  • Publication number: 20130142783
    Abstract: The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.
    Type: Application
    Filed: September 6, 2012
    Publication date: June 6, 2013
    Applicant: MEDIMMUNE, LLC
    Inventors: Anthony COYLE, Yihong Yao, Bahija Jallal, Gianluca Carlesso, Michael Bowen
  • Patent number: 8337851
    Abstract: Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.
    Type: Grant
    Filed: May 18, 2006
    Date of Patent: December 25, 2012
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
  • Patent number: 8333970
    Abstract: Methods for identifying subjects having an inflammatory disease and/or autoimmune disease that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.
    Type: Grant
    Filed: May 18, 2006
    Date of Patent: December 18, 2012
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
  • Publication number: 20120251546
    Abstract: The present disclosure encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that modulates type 1 interferon activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
    Type: Application
    Filed: September 2, 2010
    Publication date: October 4, 2012
    Applicant: MEDIMMUNE LLC
    Inventors: Brandon Higgs, Wei Zhu, Chris Morehouse, Barbara White, Bahija Jallal, Yihong Yao
  • Publication number: 20120045775
    Abstract: The present invention relates to the use of phosphorylated p21-activated protein kinases (PAK), especially PAK4, as biomarkers of tumorogenesis. The present invention contemplates the use of phosphospecific antibodies for detecting phosphorylated PAK from mammalian biopsies, as well as screening assays for identifying compounds that modulate PAK activity. Also contemplated is a method for determining a subset of a given population that is amenable to treatment with a compound that modulates PAK activity.
    Type: Application
    Filed: August 18, 2011
    Publication date: February 23, 2012
    Inventors: Tod R. SMEAL, Marinella G. CALLOW, Bahija JALLAL
  • Publication number: 20120034212
    Abstract: The present invention provides human anti-IL-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to IL-6 and that has an extended in vivo half-life for the treatment and prevention of IL-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors.
    Type: Application
    Filed: January 29, 2010
    Publication date: February 9, 2012
    Inventors: Michael Bowen, Herren Wu, William Dall' Acqua, Peter A. Kiener, Bahija Jallal, Anthony Coyle
  • Publication number: 20110287022
    Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognoses to patients having IFN?-induced disorders.
    Type: Application
    Filed: June 19, 2009
    Publication date: November 24, 2011
    Applicant: Medlmmune, LLC
    Inventors: Yihong Yao, Bahija Jallal, Ricardo Cibotti, Anthony Coyle, Peter Kiener, Barbara White
  • Publication number: 20110262928
    Abstract: The present invention encompasses miRNA profiles and type-I IFN/IFN?-induced PD marker profiles in inflammatory or autoimmune disorders, such as myositis. The profiles may also be used in, for example, methods of treating patients, methods of monitoring disease progression of patients, and in diagnosing or providing a prognosis to patients having inflammatory or autoimmune disorders.
    Type: Application
    Filed: February 6, 2009
    Publication date: October 27, 2011
    Applicant: Medimmune LLC
    Inventors: Yihong Yao, Chris Moorehouse, Brandon Higgs, Bahija Jallal, Steven A. Greenberg
  • Publication number: 20110243929
    Abstract: The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.
    Type: Application
    Filed: December 17, 2010
    Publication date: October 6, 2011
    Applicant: Medlmmune, LLC
    Inventors: Anthony COYLE, Yihong Yao, Bahija Jallal, Gianluca Carlesso, Michael Bowen
  • Publication number: 20110159532
    Abstract: The present invention relates to diagnosing abnormal cell proliferation in biological samples and screening for drugs which inhibit, reduce or abolish cell growth, especially tumorigenic cell growth, by detecting a phosphovariant isoform of a guanine nucleotide exchange factor biomarker, such as the novel GEF-H1S.
    Type: Application
    Filed: November 30, 2010
    Publication date: June 30, 2011
    Applicant: SUGEN, INC.
    Inventors: Tod R. Smeal, Marinella G. Callow, Bahija Jallal, Sergey Zozulya, Mikhail L. Gishizky